

## Curriculum Vitae Sketch

Name: JOSE ENRIQUE MARTINEZ RODRIGUEZ Position title: NEUROLOGIST  
Birth date: 26/11/1972 Citizenship: SPANISH Gender (M/F): M  
Office address: Neurology Service, Hospital del Mar, Passeig Maritim Office telephone: 932483235  
25-29, Barcelona 08003  
E-mail: [jemartinezrquez@gmail.com](mailto:jemartinezrquez@gmail.com)

---

### 1. Education / Training

| Degree | Institution             | Year(s) |
|--------|-------------------------|---------|
| MD     | University of Seville   | 1996    |
| PhD    | University of Barcelona | 2007    |

---

### 2. Professional academic positions

| Dates (from-until) | Position               | Department & Institution    |
|--------------------|------------------------|-----------------------------|
| 2005-Current       | Consultant Neurologist | Neurology, Hospital del Mar |

---

### 3. Publications (Selected from a total of 42)

*Max. of 20 international articles and/or reviews published in international journals(ISI-SCI). Please follow this order: Authors (year). Title. Journal. Volume: pages.. Please include your h-index (Web of Science)*

1. Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE. Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'? *Eur J Neurol* 2018; 25(7): 925-933. Impact factor: 4.621.
2. Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M. Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. *Mult Scler*. 2016; 22(6):741-5. Impact factor: 4.671.
3. Ortiz MA, Núñez C, Ordóñez D, Alvarez-Cermeño JC, Martínez-Rodríguez JE, Sánchez AJ, Arroyo R, Izquierdo G, Malhotra S, Montalban X, García-Merino A, Munteis E, Alcina A, Comabella M, Matesanz F, Villar LM, Urcelay E. Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. *PLoS One*. 2015 Aug 14;10(8):e0134414. Impact factor: 3.54 .
4. Martínez-Rodríguez JE, Munné-Collado J, Rasal R, Cuadrado E, Roig L, Ois A, Muntasell A, Baro T, Alameda F, Roquer J, López-Botet M. Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus. *Arterioscler Thromb Vasc Biol* 2013; 33(11): 2653-9. Impact factor: 6.0 .
5. Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. *Clin Immunol* 2011; 141: 348-356. IF: 3.863.
6. Martínez-Rodríguez JE, Saez-Borderías A, Munteis E, Romo N, Roquer J, López-Botet M (2010). Natural killer receptors Distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. *Clin Immunol* 2010; 137 (1): 41-50. Impact factor: 3.863.
7. Ordoñez D, Sánchez AJ, Martínez-Rodríguez JE, Cisneros E, Ramil E, Romo N, Moraru M, Munteis E, López-Botet M, Roquer J, García-Merino A, Vilches C (2009). Multiple Sclerosis associated with LILRA3 deletion in Spanish patients. *Genes Immun* 2009; 10: 579-85. Impact factor: 4.222.
8. Munteis E, Andreu M, Martínez-Rodríguez JE, Ois A, Bory F, Roquer J (2008). Manometric correlations of anorectal dysfunction and biofeedback outcome in patients with multiple sclerosis. *Mult Scler* 2008; 14 (2): 237-42. Impact factor: 3.279.

9. Martínez-Rodríguez JE, Munteis E, Carreño M, et al (2008). Cannabis use in Spanish patients with multiple sclerosis: fulfillment of patients' expectations?. *J Neurol Sci* 2008; 273 (1-2): 103-7. Impact factor: 2.324.
10. Martínez-Rodríguez JE, Seppi K, Cardozo A, Iranzo A, Stampfer-Kountchev M, Wenning G, Tolosa E, Högl B, Santamaria J, Poewe W (2007). Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. *Movement Disord* 2007; 22 (12): 1822-4. Impact factor: 4.014.
11. Ois A, Cuadrado-Godia E, Jiménez-Conde J, Gomis M, Rodríguez-Campello A, Martínez-Rodríguez JE, Munteis E, Roquer J (2007). Early arterial study in the prediction of mortality after acute ischemic stroke. *Stroke* 2007; 38(7): 2085-9. Impact factor: 7.041.
12. Roquer J, Ois A, Rodríguez-Campello A, Gomis M, Munteis E, Jiménez-Conde J, Cuadrado-Godia E, Martínez-Rodríguez JE (2007). Clustering of vascular risk factors and in-hospital death after acute ischemic stroke. *J Neurol* 2007; 254 (12): 1636-41. Impact factor: 2.903.
13. Martínez-Rodríguez JE, Cadavid D, Wolansky L, Pliner L (2007). Cladribine in aggressive forms of multiple sclerosis. *Eur J Neurol* 2007; 14(6): 686-9. Impact factor: 2.510.
14. Martínez-Rodríguez JE, Sabater L, Graus F, Iranzo A, Santamaría J (2007). Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. *Sleep* 2007; 30(1): 27-8. Impact factor: 5.402.
15. Martínez-Rodríguez JE, Iranzo A, Casamitjana R, Graus F, Santamaría J (2007). Análisis comparativo de un grupo de pacientes con narcolepsia-cataplejía, narcolepsia sin cataplejía e hipersomnia idiopática. *Med Clin* 2007; 128(10): 361-4. Impact factor: 1.231.
16. Martínez-Rodríguez JE, Munteis E, Roquer J (2006). Periodic hyperthermia and abnormal circadian rhythm in a patient with multiple sclerosis. *Mult Scler* 2006; 12: 515-517. Impact factor: 3.279..
17. Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C, Martínez-Rodríguez JE, Vincent A, Santamaria J (2006). Rapid eye movement sleep behaviour disorder and potassium channel antibody-associated limbic encephalitis. *Ann Neurol* 2006; 59: 178-81. Impact factor: 9.317.
18. Martínez Rodríguez JE, Sanchez-Valle R, Saiz A, Lin L, Iranzo A, Mignot E, Santamaria J (2003). Normal CSF hypocretin-1 (Orexin-A) levels in patients with fatal familial insomnia. *Sleep* 2003; 26: 1068. Impact factor: 5.402..
19. Martínez Rodríguez JE, Lin L, Iranzo A, Genis D, Marti MJ, Santamaria J, Mignot E (2003). Decreased CSF Hypocretin-1 (Orexin-A) levels in myotonic dystrophy patients with excessive daytime sleepiness. *Sleep* 2003; 26 (3): 287-290. Impact factor: 5.402.
20. Martínez Rodríguez JE, Barriga FJ, Santamaria J, Iranzo A, Pareja JA, Revilla M, de la Rosa CR (2001). Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. *Am J Med* 2001;111: 115-119. Impact factor: 4.466.

H-index: 15

---

#### **4. Research Grants** (only competitive)

*As Principal Investigator ( last 6 years). Please follow this order: Title, funding organization, institution, code n., duration*

**Martínez-Rodríguez JE.** Carotid atherosclerosis and innate immune response to cytomegalovirus. Ministerio de Ciencia e Innovación, Plan Nacional 2011-2013. SAF2010-22153-CO3-02. Duration: 3 years.

**Martínez-Rodríguez JE.** Estudio del valor pronóstico en la Esclerosis Múltiple de un nuevo biomarcador asociado a la infección por citomegalovirus. FIS P114/00177. 2015-2017. Duration: 3 years.

**Martínez-Rodríguez JE.** Respuesta adaptativa mediada por células Natural Killer en la Esclerosis Múltiple. FIS P117/00254. 2018-2020. Duration: 3 years.

---

## **5. License agreements, clinical trials (phase I-II), other contracts with companies**

*(Last 6 years) Indicate whether it is a service contract or it is a research collaboration*

1.- NCT01194570. A Phase III, multicentre, randomized, parallel-group, double-blind, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis. Sponsor: F.Hoffmann-La Roche Ltd.

Period: 2011-ongoing.

PI: Jose Enrique Martínez Rodríguez.

2.- NCT01412333. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis. Sponsor: F.Hoffmann-La Roche Ltd.

Period: 2011-ongoing.

PI: Jose Enrique Martínez Rodríguez.

3.- EudraCT 2010-023048-34. A phase IIa multicenter double blind study to evaluate the efficacy and safety of low doses of oral diazoxide for the treatment of multiple sclerosis.

Sponsor: NEUROTEC PHARMA, S.L

Period: 2012-2014.

PI: Jose Enrique Martínez Rodríguez.

4.- NCT01324232. A phase 2, double-blind, randomized, placebo-controlled, four-arm, multicenter, dose-finding study to assess the safety and efficacy of three dose levels of AVP-923 (dextromethorphan/quinidine) in the treatment of central neuropathic pain in patients with multiple sclerosis. Sponsor: Avanir Pharmaceuticals, Inc.

Period: 2012-2013.

PI: Jose Enrique Martínez-Rodríguez.

5.- NCT01665144. A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis. Sponsor: Novartis.

Period: 2013-ongoing.

PI: Jose Enrique Martínez Rodríguez.

6.- NCT01742052.

A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis. Sponsor: Mitsubishi Pharma Europe Ltd.

Period: 2013-2014.

PI: Jose Enrique Martínez Rodríguez.

7.- EudraCT number 109,159/2012-002714-40. A phase 2/3, multi-center, randomized, double-blind, placebo controlled (part A) and double-blind, double-dummy, active controlled (part B), parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients. Sponsor: Receptos, Inc.

Period: 2013 - 2017.

PI: Jose Enrique Martínez Rodríguez.

8.- Eudra CT number: 2010-021219-17. Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitinib a la dosis de 4.5 mg/kg/día con placebo en el tratamiento de pacientes con esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva sin recidiva. Sponsor: AB Science.

Period: 2015- ongoing.

PI: Jose Enrique Martínez Rodríguez.

9.- EUDRACT NUMBER: 2015-005597-38. Estudio abierto para evaluar la eficacia y la seguridad de ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad. Sponsor: F.Hoffmann-La Roche Ltd.

Period: 2016-1017.

PI: Jose Enrique Martínez Rodríguez.

10.- EUDRACT NUMBER: 2012-000540-10. Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, de superioridad, con control activo, para comparar la eficacia y seguridad de ponesimod frente a teriflunomida en sujetos con esclerosis múltiple recidivante. Sponsor: Actelion. Period: 2016-2018. PI: PI: Jose Enrique Martínez Rodríguez.

11.- EUDRACT NUMBER: 2017-002838-23. Randomised, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS). Sponsor: ORYZON. Period: 2018-2019. PI: Jose Enrique Martínez Rodríguez.

12. EUDRACT NUMBER: 2016-001448-21. Estudio en fase ii aleatorizado, doble ciego y controlado con placebo sobre m2951 con un grupo de control activo, paralelo y abierto (tecfidera) en pacientes con esclerosis múltiple recidivante para evaluar la eficacia, seguridad, tolerabilidad, farmacocinética y actividad biológica. Sponsor: Merck. Period: 2016-2019. PI: Jose Enrique Martínez Rodríguez.

13. EUDRACT NUMBER: 2015-005418-31. Estudio aleatorizado, doble ciego, doble enmascarado, de grupos paralelos para comparar la eficacia y seguridad de ofatumumab frente a teriflunomida en pacientes con esclerosis múltiple que cursa con brotes. Sponosr: Novartis. Period: 2017-2020. PI: Jose Enrique Martínez Rodríguez.

---

## **6. Patents**

Title: Patent ID: Date: Inventors: Exploitation:  No  Yes

---

## **7. International Conferences**

*Max. of 10 as invited speaker in the last 6 years. Please follow this order: Name of the congress, speech title, place & year*

*European Sleep Research Society. Excessive daytime sleepiness in myotonic dystrophy: the role of hypocretin. Glasgow 2008.*

## **8. Ph.D Thesis Director**

Number of thesis accomplished:

## **9. Honours and other professional activities**

**Dates** (from-until)      **Description**

---

## **10. Any other relevant information you may consider worth mentioning**

*(Limit extension to 10 lines max )*

## SUMMARY OF RESEARCH ACTIVITY

Name of the PI: JOSE ENRIQUE MARTINEZ RODRIGUEZ

### Resources

#### Activity indicators (last 6 years)

- Funding from
  - N. of competitive grants obtained: 4
  - N. of research contracts with industry: 13
  - N. of clinical trials (Phase I-II): 4. N. of clinical trials (Phase III): 9
  - N. of European projects (as *participant*): 1 N. of European projects (as *coordinator*): 0
  - National networks: No X Yes External services: X No  Yes
- Scientific production: N. of articles and/or reviews (ISI-SCI) : 40
- Selected articles/reviews published in the indicated period (max 10). Follow format as indicated in point 3
  - 1) Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE. Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'? Eur J Neurol 2018; 25(7): 925-933. .
  - 2) Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M. Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Mult Scler. 2016; 22(6):741-52.
  - 3) Ortiz MA, Núñez C, Ordóñez D, Alvarez-Cermeño JC, Martínez-Rodríguez JE, Sánchez AJ, Arroyo R, Izquierdo G, Malhotra S, Montalban X, García-Merino A, Munteis E, Alcina A, Comabella M, Matesanz F, Villar LM, Urcelay E. Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS One. 2015 Aug 14;10(8):e0134414.
  - 4) López-Botet M, Muntasell A, Martínez-Rodríguez JE, López-Montañés M, Costa-García M, Pupuleku A. Development of the adaptive NK cell response to human cytomegalovirus in the context of aging. Mech Ageing Dev. 2016 Jun 24.
  - 5) Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e147.
  - 6) Cuadrado-Godia E, Jimena S, Ois A, Rodríguez-Campello A, Giralte-Steinhauer E, Soriano-Tarraga C, Jiménez-Conde J, Martínez-Rodríguez JE, Capellades J, Roquer J. Factors associated with early outcome in patients with large-vessel carotid strokes. J Neurol Neurosurg Psychiatry. 2013 ;84(3):305-9.
  - 7) Martínez-Rodríguez JE, Munné-Collado J, Rasal R, Cuadrado E, Roig L, Ois A, Muntasell A, Baro T, Alameda F, Roquer J, López-Botet M. Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus. Arterioscler Thromb Vasc Biol 2013; 33(11): 2653-9.
  - 8) Roquer J, Cuadrado-Godia E, Giralte-Steinhauer E, Jimena S, Jiménez-Conde J, Martínez-Rodríguez JE, Ois A, Rodríguez-Campello A. Previous infection and stroke: a prospective study. Cerebrovasc Dis. 2012;33(4):310-5.
  - 9) Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in múltiple sclerosis. Clin Immunol 2011; 141: 348-356. IF: 3.863.
  - 10) Martínez-Rodríguez JE, Saez-Borderias A, Munteis E, Romo N, Roquer J, López-Botet M (2010). Natural killer receptors Distribution in múltiple sclerosis: Relation to clinical course and interferon-beta therapy. Clin Immunol 2010; 137 (1): 41-50.

---

**Active External collaborations** (name of researcher, institution, city & country)

**Red Española de Esclerosis Múltiple, IMIM group (IP: M.López-Botet). ISCIII, RD12/0032/0016, RD16/0015/0011**

**Summary of current research lines and future prospects** (include title, introduction, objectives, selected references ...)

Lines of research are included into the **Neuroimmunology** line under the group Immunity and Infection:

The focus of our group is the study of the pathophysiology of multiple sclerosis, evaluating the impact that common viral infections such as herpesviruses may have on lymphocyte compartments, and their influence on the clinical course of the disease. Within the Spanish Network of Multiple Sclerosis, we aim to develop potential biomarkers based on this approach that may be used for selection of the patients with a high risk of disability progression. In addition, we are currently carrying on several international Phase II and III clinical trials of new disease-modifying drugs for multiple sclerosis patients.

---